NASDAQ:FBIOFortress Biotech Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Fortress Biotech Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.86 +0.02 (+0.70 %) (As of 07/10/2020 04:00 PM ET) Add Compare Share Today's Range$2.75Now: $2.86▼$2.8850-Day Range$2.54MA: $2.84▼$3.1652-Week Range$1.04Now: $2.86▼$3.20Volume558,900 shsAverage Volume634,676 shsMarket Capitalization$235.88 millionP/E RatioN/ADividend YieldN/ABeta2.19 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. It markets dermatology products, such as Targadox for acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; Ala-Scalp and Triderm, which are used for the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; and Ala-Quin, an antibacterial and antifungal cream. The company also develops MB-107, a gene therapy for X-linked severe combined immunodeficiency; CAEL-101, a Phase Ia/Ib trial that reduces amyloid deposits in the tissues and organs; CD123 chimeric antigen receptor engineered T-cell (CAR T) program for acute myeloid leukemia; CD20 CAR T program for B cell non-Hodgkin lymphoma; and CS1 CAR T for multiple myeloma and light chain amyloidosis. In addition, it develops MB-101 for Glioblastoma (GBM); MB-103 for GBM, and breast cancer and brain metastases; MB-105 for prostate and pancreatic cancers; intravenous Tramadol for post-operative pain; CK-101, a Phase I/II clinical trial for treating patients with EGFR mutation-positive non-small cell lung cancer; CK-301, a Phase I clinical trial for metastatic cancer; Triplex, a Phase I study recombinant modified vaccinia ankara viral vector vaccine; ConVax, a recombinant modified vaccinia ankara viral vector vaccine; CEVA-101 for traumatic brain injury; CEVA-D, a bioreactor device that enhances the anti-inflammatory potency of bone marrow-derived cells; Tamid-001, a gene therapy for mucopolysaccharidosis type I disorder; CNDO-109, a lysate that activates donor natural killer cells; and methazalomide products. The company has collaboration arrangements with some universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingFortress Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.50, Fortress Biotech has a potential upside of 267.1% from its current price of $2.86.Amount of Analyst CoverageFortress Biotech has only been the subject of 2 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesFortress Biotech has received 284 “outperform” votes. (Add your “outperform” vote.)Underperform VotesFortress Biotech has received 259 “underperform” votes. (Add your “underperform” vote.)Community SentimentFortress Biotech has received 52.30% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Fortress Biotech and other stocks. Vote “Outperform” if you believe FBIO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FBIO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldFortress Biotech does not currently pay a dividend.Dividend GrowthFortress Biotech does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fortress Biotech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 33.10% of the stock of Fortress Biotech is held by insiders.Percentage Held by InstitutionsOnly 15.79% of the stock of Fortress Biotech is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Fortress Biotech are expected to grow in the coming year, from ($1.02) to ($0.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fortress Biotech is -3.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fortress Biotech is -3.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFortress Biotech has a P/B Ratio of 2.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.35 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:FBIO Previous Symbol CUSIP21976U10 CIK1429260 Webwww.fortressbiotech.com Phone781-652-4500Debt Debt-to-Equity Ratio1.26 Current Ratio3.07 Quick Ratio3.05Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$36.63 million Price / Sales6.44 Cash FlowN/A Price / Cash FlowN/A Book Value$1.02 per share Price / Book2.80Profitability EPS (Most Recent Fiscal Year)($0.73) Net Income$-39,960,000.00 Net Margins-124.73% Return on Equity-58.31% Return on Assets-20.17%Miscellaneous Employees93 Outstanding Shares82,474,000Market Cap$235.88 million Next Earnings Date8/14/2020 (Estimated) OptionableOptionable NASDAQ:FBIO Rates by TradingView Receive FBIO News and Ratings via Email Sign-up to receive the latest news and ratings for FBIO and its competitors with MarketBeat's FREE daily newsletter. Fortress Biotech (NASDAQ:FBIO) Frequently Asked Questions How has Fortress Biotech's stock been impacted by COVID-19 (Coronavirus)? Fortress Biotech's stock was trading at $1.61 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, FBIO stock has increased by 77.6% and is now trading at $2.86. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Fortress Biotech? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Fortress Biotech. When is Fortress Biotech's next earnings date? Fortress Biotech is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Fortress Biotech. How were Fortress Biotech's earnings last quarter? Fortress Biotech (NASDAQ:FBIO) posted its earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.24) by $0.05. The biopharmaceutical company had revenue of $12.92 million for the quarter, compared to analyst estimates of $11.44 million. Fortress Biotech had a negative return on equity of 58.31% and a negative net margin of 124.73%. View Fortress Biotech's earnings history. What price target have analysts set for FBIO? 4 equities research analysts have issued 12 month target prices for Fortress Biotech's shares. Their forecasts range from $6.00 to $19.00. On average, they expect Fortress Biotech's stock price to reach $10.50 in the next year. This suggests a possible upside of 267.1% from the stock's current price. View analysts' price targets for Fortress Biotech. Has Fortress Biotech been receiving favorable news coverage? Media headlines about FBIO stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Fortress Biotech earned a coverage optimism score of -1.8 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about Fortress Biotech. Are investors shorting Fortress Biotech? Fortress Biotech saw a increase in short interest in June. As of June 30th, there was short interest totaling 539,000 shares, an increase of 17.3% from the June 15th total of 459,600 shares. Based on an average daily volume of 640,500 shares, the short-interest ratio is currently 0.8 days. Currently, 0.9% of the shares of the company are short sold. View Fortress Biotech's Current Options Chain. Who are some of Fortress Biotech's key competitors? Some companies that are related to Fortress Biotech include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Ionis Pharmaceuticals (IONS). View all competitors. What other stocks do shareholders of Fortress Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fortress Biotech investors own include Advanced Micro Devices (AMD), TG Therapeutics (TGTX), Vaxart (VXRT), Sorrento Therapeutics (SRNE), Amarin (AMRN), Crispr Therapeutics (CRSP), VBI Vaccines (VBIV), Anavex Life Sciences (AVXL), Dynavax Technologies (DVAX) and Geron (GERN). Who are Fortress Biotech's key executives? Fortress Biotech's management team includes the following people: Dr. Lindsay Allan Rosenwald, Exec. Chairman, Pres & CEO (Age 65, Pay $532.57k)Ms. Robyn M. Hunter, CFO, Treasurer & Corp. Sec. (Age 58, Pay $1.8M)Mr. George C. Avgerinos, Sr. VP of Biologics Operations (Age 66, Pay $386.35k)Mr. Michael S. Weiss, Exec. Vice Chairman of Strategic Devel. & Director (Age 54, Pay $532.57k)Dr. Thomas F. Schaible, Project Leader of Inflammatory Bowel Disease What is Fortress Biotech's stock symbol? Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO." How do I buy shares of Fortress Biotech? Shares of FBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Fortress Biotech's stock price today? One share of FBIO stock can currently be purchased for approximately $2.86. How big of a company is Fortress Biotech? Fortress Biotech has a market capitalization of $235.88 million and generates $36.63 million in revenue each year. The biopharmaceutical company earns $-39,960,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis. Fortress Biotech employs 93 workers across the globe. What is Fortress Biotech's official website? The official website for Fortress Biotech is www.fortressbiotech.com. How can I contact Fortress Biotech? Fortress Biotech's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 781-652-4500 or via email at [email protected] This page was last updated on 7/11/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
